Welcome to the 5th edition of Mareana Deep Dive. This version covers our updates from October and November 2025. So, here we go:

[Blog] Accelerating Tech Transfer with AI and Data Driven Approach

The pharmaceutical industry is increasingly reliant on Contract Development and Manufacturing Organizations (CDMOs) to get life-saving therapies to market. This trend makes the technology transfer process between a brand sponsor and their CDMO more critical than ever, as it requires a high degree of trust, transparency, and seamless collaboration between two separate organizations. Despite this, tech transfer is often treated as a one-way, linear handoff, rather than an ongoing partnership.

The conventional approach relies on a static “technology transfer package” that is compiled and handed over, with formal meetings serving as a limited opportunity for clarification. The process of compiling this package is frequently a manual, labor-intensive effort, prone to human error and data fragmentation. This outdated method creates significant bottlenecks, especially during critical stages like batch record review and release, which can lead to costly delays and frustrate stakeholders across the board.

👉 Read our blog to understand how you can leverage AI data driven approach to overcome the challenges of traditional methods and achieve faster and accurate tech transfer.

[Blog] Mareana recognized by Gartner in their Hype Cycle Issue 2025

Every year Gartner creates close to 100 hype cycles to help business leaders make informed decisions about their technology investments. It does that by showing how technologies evolve over time, helping leaders separate hype from real value and avoid risky investments.

While we’ll explain the Hype Cycle in more detail in this article, we’re proud to share that Mareana has been recognized twice as a Sample Vendor in Gartner’s Hype Cycle

👉 Read Mareana recognized by Gartner in their Hype Cycle Issue 2025

[Featured Article] AI and SaaS: reshaping business outcomes in pharma manufacturing

How is artificial intelligence, when delivered through software as a service platform, unlocking real business outcomes for pharmaceutical manufacturers, from faster batch release and smarter investigations to smoother tech transfers and enterprise-wide compliance?

Innovations in Pharmaceutical Technology, a leading magazine in the industry, recently published an article by our CPO and Co-founder, Mr. Vishal Prasad. The article explains the amalgamation of SaaS and AI, and its transformative business outcomes.

👉 You can read the article on the magazine’s website.

[Video] Balancing cost and resiliency in the volatile tariff landscape

Listen to John Wang, Managing Director, L Catterton, sharing his views in this video on LinkedIn.

👉 Watch the video

[Video] What is the near-term perspective on tariffs in the pharma industry?

With tariffs remaining highly unpredictable, many organizations are taking a more short-term view as they navigate ongoing uncertainty. In this clip, Vishal Prasad, Chief Product Officer at Mareana, shares what he’s hearing from clients.

👉 Watch the short clip here

[Video] How technology can help manage the volatility in tariffs?

Hear what the experts think about managing the volatility of tariffs by leveraging technology.

👉  Watch the video here

[Inside Mareana] Team Outing, Rewards, and Recognition

[Inside Mareana] AI @ Floor: Our efforts to build an AI-first culture

Get the next edition of Mareana Deep Dive straight to your inbox – subscribe to our newsletter.